电在神经疾病中对认知障碍的保护作用
Yueyang Xin1, Siqi Zhou1, Tiantian Chu1
1Department of Anesthesiology, Hubei Key Laboratory of Geriatric Anesthesia and Perioperative Brain Health, and Wuhan Clinical Research Center for Geriatric Anesthesia, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Current neuropharmacology
|February 21, 2024
概括
电针 (EA) 显示出治疗神经疾病的认知障碍的前景,有效改善症状并影响关键的分子通路. 需要进一步的研究才能充分理解它对阿尔茨海默氏症等疾病的机制.
科学领域:
- 神经科学是一个神经科学.
- 传统中国医药 传统中国医药
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经系统疾病经常导致认知障碍,包括痴呆症和轻度认知障碍,造成重大负担.
- 目前用于认知障碍的药理疗法有效性有限,需要探索替代疗法.
- 电针 (EA) 是中国传统医学的关键技术,为认知障碍提供了潜在的治疗途径.
研究的目的:
- 系统地审查关于电针 (EA) 对神经疾病认知障碍的疗效的临床前证据.
- 阐明EA对认知功能的治疗作用背后的分子机制.
- 确定EA已经证明了潜在益处的神经疾病模型.
主要方法:
- 在2022年10月之前发表的临床前研究的系统文献搜索.
- 搜索的数据库包括PubMed,科学网络,MEDLINE,奥维德和Embase.
- 纳入标准侧重于研究EA对神经疾病模型认知障碍的影响.
主要成果:
- 在各种临床前神经疾病模型中,EA有效改善认知障碍.
- EA影响多个分子通路,包括那些涉及神经炎症,神经细胞亡,神经发生,突触可塑性和自的.
- 在阿尔茨海默病,血管认知障碍,慢性疼痛和帕金森病的模型中观察到有益的影响.
结论:
- 电针 (EA) 是一种有前途的治疗方法,可以缓解与神经系统疾病相关的认知障碍.
- EA通过多样化和潜在的重叠分子机制来发挥其治疗作用.
- 需要进一步的研究,以充分阐明EA对认知障碍的详细机制.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
125
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
125
01:23Role of Neurotransmitters in Memory
553
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
553
01:22Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189
01:26Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
01:30Electroconvulsive Therapy
39
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
39